Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL: Fexagratinib + AI in ER+ Breast Cancer
NCT01791985Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Jul 2012
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib in estrogen receptor-positive breast cancer (ER+), sponsored by Imperial College London. Started Jul 2012; status: completed.
02
Drugs
fexagratinib
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT01791985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01791985.